News
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...
5d
Zacks Investment Research on MSNVertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...
The Oxalosis and Hyperoxaluria Foundation (OHF) has accepted UCSF Health into its OHF Care Center Network recognizing the health system’s dedication to providing high-quality medical care, resources, ...
Brandon Kistler, PhD, RD, took a kidney disease dietetic internship in college that changed the course of his career. He noticed a gap between traditional nutrition advice for patients with kidney ...
Loss of p300 in proximal tubular cells reduces renal fibrosis and endothelial-mesenchymal transition
Chronic kidney disease (CKD) is typically associated with severe fibrosis, the exact pathogenesis of which remains unclear.
5d
HealthDay on MSNEmpagliflozin Has Kidney Protective Effects in Acute Myocardial InfarctionTotal adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.
Harnessing the power of a metabolite produced in the kidneys and absorbed from certain foods can mimic the health benefits ...
A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease. Monogenic lupus nephritis is distinct from non-monogenic disease with ...
AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining forces with Aptar to develop algorithms that can be used to detect CKD ...
Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or ...
Proton pump inhibitor use is implicated in decline in kidney graft function after transplantation. Extended proton pump inhibitor (PPI) use is associated with decline in graft function in kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results